CDK4/6 inhibitors in advanced breast cancer, what is beyond?

Resistant to hormonal treatment considered the main clinical challenge in the management of advanced breast cancer (ABC). The use of CDK4/6 inhibitors (CDK4/6I) may change the treatment landscape. In this mandated review, we will focus on the applicable role of CDK4/6I in the management of HR+/HER2-...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohammed, Amrallah A., Rashied, Hanaa, Elsayed, Fifi Mostafa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: PAGEPress Publications, Pavia, Italy 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6683209/
https://www.ncbi.nlm.nih.gov/pubmed/31452841
http://dx.doi.org/10.4081/oncol.2019.416

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6683209/
https://www.ncbi.nlm.nih.gov/pubmed/31452841
http://dx.doi.org/10.4081/oncol.2019.416

Ejemplares similares